An investigational RNAi therapeutic targeting Factor XII (ALN-F12) for the treatment of hereditary angioedema

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

FIGURE 2.
FIGURE 2.

ALN-F12 dose-dependent knockdown of circulating FXII in mice and rats. (A) Female C57BL/6J mice were subcutaneously administered a single dose of ALN-F12 (n = 3 per group). Plasma FXII levels were measured by ELISA and normalized to PBS control group. (B) Female Sprague–Dawley rats were subcutaneously administered a single dose of ALN-F12 (n = 3 per group). Plasma FXII levels were measured by ELISA and normalized to the average of PBS control group. Error bars are SD.

This Article

  1. Published in Advance November 21, 2018, doi: 10.1261/rna.068916.118 RNA 25: 255-263

Current Issue

  1. August 2026, 32 (8)
  1. Current Issue
  1. Alert me to new issues of RNA